Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

Published Date: 18 Oct 2024

Odds of undetectable PSA at 48 weeks doubled with addition of Pluvicto

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

2.

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

3.

Encounters matter in cancer care: Health care professionals can play a key role in restoring patients' sense of control

4.

Cancer care crowdfunding increasingly common, but rarely successful

5.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot